Catabasis Pharma (CATB): Investor Day Summary - Wedbush

November 18, 2016 7:19 AM EST
Get Alerts CATB Hot Sheet
Price: $3.46 +0.29%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade CATB Now!
Join SI Premium – FREE

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

Wedbush analyst, Liana Moussatos, reiterated her Outperform rating on shares of Catabasis (NASDAQ: CATB) after attending the company's analyst day. CATB’s management and KOLs discussed the company’s lead program, edasalonexent (edasa) for DMD, and provided an overview of the clinical landscape and natural history of DMD and use of magnetic resonance imaging (MRI) in DMD. Top-line results from the company’s ongoing MoveDMD trial for edasa are expected in the first half of Q1:17.

The analyst believes the stock offers a compelling risk/reward and reiterated his price target of $15.

For an analyst ratings summary and ratings history on Catabasis click here. For more ratings news on Catabasis click here.

Shares of Catabasis closed at $4.31 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Management Comments

Related Entities

Liana Moussatos

Add Your Comment